Navigation Links
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Date:4/9/2012

the combination in tumor cells while potentially identifying biomarkers for patient selection in subsequent studies. 

"This study represents our continued commitment to work with the NCI and our industry and academic collaborators to expand the ENCORE (ENtinostat Combinations Overcoming REsistance) platform aimed at overcoming resistance to targeted therapies in breast cancer and other solid tumors," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "With our recently reported positive data in ENCORE 301 targeting ER+ breast cancer and the NCI sponsored study NCT01234532 combining entinostat with Arimidex in ER-, PR-, HER2- triple negative breast cancer we are pleased to be in a position to provide proof-of-concept clinical data across all segments of breast cancer."

About Entinostat

Syndax's lead product entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. Entinostat is differentiated from other members of the class through its unique selectivity profile, pharmacokinetic properties and safety profile. Entinostat has been studied in more than 600 cancer patients where objective tumor responses have been observed in breast and lung cancer and hematologic malignancies. Randomized, placebo-controlled phase 2 studies with entinostat have demonstrated promising results in combination with aromatase inhibitors in breast cancer (ENCORE 301) and with the EGFR-TKI erlotinib (ENCORE 401) in non-small cell lung cancer.  Results from the ENCORE clinical program have provided the basis for moving entinostat in pivotal, phase 3 testing across a platform of breast and lung cancer indications. NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Develo
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals to Present at BIO Investor Forum
2. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 A leading manufacturer of ... slated to discuss its custom fabrication services today at ... website, which launched just prior to the INTERPHEX event. ... 21, 22 and 23) at the Javits Center in ... the world’s largest and most innovative pharmaceutical and biotech ...
(Date:4/20/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a ... cancer therapies in new orphan drug indications, today ... Annual Meeting of the American Association for Cancer ... for its lead product candidate VAL-083 ...
(Date:4/20/2015)... Calif. , April 20, 2015 PointCross ... Pvt. Ltd. to provide an integrated Big Data and ... all biomarkers collected in the context of clinical trials ... of precise or multi-targeted drug candidates, stratified patient selection ... disease progression free survival. Highlighting the ...
(Date:4/20/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC ... announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ... one of its proprietary human-derived CPP sequences and a ... of NFkB signalling even if administered when the BBB ... blood brain barrier (BBB) in mice was studied and ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3
... , a provider of molecular diagnostics solutions, reported losses in ... Wave reported total revenue of $5.8 million and a net ... for the quarter ended June 30, 2005, compared to total ... and zero cents per diluted share for the same period ...
... Third Wave Technologies Inc., a developer and provider ... chairman of the company's board of directors, replacing company ... the business's planned transition. , ,Thompson, 63, was the ... of Abbott Laboratories , an Illinois-based medical products ...
... Corp ., a Waukesha-based supply chain technology ... enabling Cooper Lighting , a George-based ... distribution operations and workforce productivity. , ,The ... with RedPrairie's DLx Warehouse, slotting and workforce ...
Cached Biology Technology:Transition continues to impact Third Wave financials 2
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of a new gene is helping researchers at Michigan ... A team of researchers, led by Katherine Osteryoung, ... a new class of proteins in the ... Academy of Sciences . CLMP1 plays a key role ...
... aid cavity-nesting ducks can prove to be turtle death traps. ... Educator Associate Professor Denis Conover, of the Department of Biological ... he came upon a duck nest box in the wetlands ... over. Turtle corpses were strewn about the mud and mire ...
... living in family or group homes are less ... living in institutions, according to University of Louisville ... Ph.D. These individuals also are more likely than ... increased decay and gum disease, factors that may ...
Cached Biology News:Discovery of new gene could improve efficiency of molecular factories 2UC research finds that a duck's boon might be a turtle's bane 2UofL researcher to develop oral health plan for those with IDD 2
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
... Fluorescein 6-Fam, Hex, Tet Cy3, Cy5, ... Tamra Black Hole Quenchers Molecular Beacons* ... Tamra, Joe 3 Dabcyl Dabcyl*Licensed ... York Double labelled probes are purified either ...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity (1). Novagen&'s enzyme ... to yield the highest activity available, and ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Biology Products: